Chapter 1. Executive Summary
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2019-2027 (USD Billion)
1.2.1. Antibody Drug Conjugate Market , by Region, 2019-2027 (USD Billion)
1.2.2. Antibody Drug Conjugate Market , by Technology, 2019-2027 (USD Billion)
1.2.3. Antibody Drug Conjugate Market , by Application, 2019-2027 (USD Billion)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
Chapter 2. Global Antibody Drug Conjugate Market Definition and Scope
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Scope of the Study
2.2.2. Industry Evolution
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
Chapter 3. Global Antibody Drug Conjugate Market Dynamics
3.1. Antibody Drug Conjugate Market Impact Analysis (2019-2027)
3.1.1. Market Drivers
3.1.1.1. Growing Geriatric Population Base
3.1.1.2. Increasing Incidence and Prevalence of Cancer
3.1.2. Market Restraint
3.1.2.1. High Manufacturing Cost of Antibody-Drug Conjugates and Challenges in Downstream Processing of ADCs
3.1.2.2. Stringent Reimbursement Policies for ADCs
3.1.3. Market Opportunities
3.1.3.1. Presence of Strong Product Pipeline
Chapter 4. Global Antibody Drug Conjugate Market Industry Analysis
4.1. Porter's 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter's 5 Force Model (2018-2027)
4.2. PEST Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.3. Investment Adoption Model
4.4. Analyst Recommendation & Conclusion
Chapter 5. Global Antibody Drug Conjugate Market , by Technology
5.1. Market Snapshot
5.2. Global Antibody Drug Conjugate Market by Technology, Performance - Potential Analysis
5.3. Global Antibody Drug Conjugate Market Estimates & Forecasts by Technology 2018-2027 (USD Billion)
5.4. Antibody Drug Conjugate Market , Sub Segment Analysis
5.4.1. Cleavable Linker
5.4.2. Non-cleavable Linker
5.4.3. Linker less
Chapter 6. Global Antibody Drug Conjugate Market , by Application
a. Market Snapshot
6.1. Global Antibody Drug Conjugate Market by Application, Performance - Potential Analysis
6.2. Global Antibody Drug Conjugate Market Estimates & Forecasts by Application 2018-2027 (USD Billion)
6.3. Antibody Drug Conjugate Market , Sub Segment Analysis
6.3.1. Blood Cancer
6.3.2. Multiple Myeloma
6.3.3. Breast Cancer
6.3.4. Urothelial Cancer & Bladder Cancer
6.3.5. Others
Chapter 7. Global Antibody Drug Conjugate Market , Regional Analysis
7.1. Antibody Drug Conjugate Market , Regional Market Snapshot
7.2. North America Antibody Drug Conjugate Market
7.2.1. U.S. Antibody Drug Conjugate Market
7.2.1.1. Technology breakdown estimates & forecasts, 2018-2027
7.2.1.2. Origin breakdown estimates & forecasts, 2018-2027
7.2.1.3. Application breakdown estimates & forecasts, 2018-2027
7.2.2. Canada Antibody Drug Conjugate Market
7.3. Europe Antibody Drug Conjugate Market Snapshot
7.3.1. U.K. Antibody Drug Conjugate Market
7.3.2. Germany Antibody Drug Conjugate Market
7.3.3. France Antibody Drug Conjugate Market
7.3.4. Spain Antibody Drug Conjugate Market
7.3.5. Italy Antibody Drug Conjugate Market
7.3.6. Rest of Europe Antibody Drug Conjugate Market
7.4. Asia-Pacific Antibody Drug Conjugate Market Snapshot
7.4.1. China Antibody Drug Conjugate Market
7.4.2. India Antibody Drug Conjugate Market
7.4.3. Japan Antibody Drug Conjugate Market
7.4.4. Australia Antibody Drug Conjugate Market
7.4.5. South Korea Antibody Drug Conjugate Market
7.4.6. Rest of Asia Pacific Antibody Drug Conjugate Market
7.5. Latin America Antibody Drug Conjugate Market Snapshot
7.5.1. Brazil Antibody Drug Conjugate Market
7.5.2. Mexico Antibody Drug Conjugate Market
7.6. Rest of The World Antibody Drug Conjugate Market
Chapter 8. Competitive Intelligence
8.1. Top Market Strategies
8.2. Company Profiles
8.2.1. Takeda Pharmaceutical Company Limited
8.2.1.1. Key Information
8.2.1.2. Overview
8.2.1.3. Financial (Subject to Data Availability)
8.2.1.4. Product Summary
8.2.1.5. Recent Developments
8.2.2. F. Hoffmann-La Roche Ltd.
8.2.3. Pfizer, Inc.
8.2.4. Astrazeneca
8.2.5. Gilead Sciences, Inc.
8.2.6. Astellas Pharma
8.2.7. Seagen, Inc.
8.2.8. Daiichi Sankyo Company, Limited
8.2.9. GlaxoSmithKline Plc
8.2.10. ADC Therapeutics

Chapter 9. Research Process
9.1. Research Process
9.1.1. Data Mining
9.1.2. Analysis
9.1.3. Market Estimation
9.1.4. Validation
Publishing
9.2. Research Attributes
9.3. Research Assumption